7ZA.F ASCELIA PHARMA AB
- Market cap
- EUR 5.21M
- P/E
- -
- P/B
- 0.66x
- ROE
- -63.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7ZA.F undervalued?
Graham numberThe Graham number of ASCELIA PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ASCELIA PHARMA AB fundamental analysis
No fundamental analysis for ASCELIA PHARMA AB yet.
ASCELIA PHARMA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ASCELIA PHARMA AB
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncol…
Full company profileASCELIA PHARMA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ASCELIA PHARMA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -148M | -111M | -68.1M | -74.1M | -58.5M |
| EBITDA | -133M | -110M | -76.4M | -75.0M | -57.4M |
| Net Income | -131M | -109M | -80.0M | -76.3M | -57.2M |
| EPS | -2.70 | -2.24 | -0.83 | -0.60 | -0.42 |
| Balance Sheet | |||||
| Total Assets | 219M | 87.1M | 141M | 112M | 100M |
| Total Liabilities | 37.7M | 12.7M | 62.0M | 12.5M | 10.4M |
| Shareholders' Equity | 181M | 74.3M | 78.9M | 99.5M | 89.8M |
| Cash & Short-term Investments | 150M | 21.9M | 75.3M | 49.9M | 38.0M |
| Cash Flow | |||||
| Operating Cash Flow | -125M | -127M | -62.8M | -72.3M | -59.7M |
| Capital Expenditure | 65.0K | 0.00 | 0.00 | 57.0K | 0.00 |
| Free Cash Flow | -125M | -127M | -62.8M | -72.3M | -59.7M |
| Ratios | |||||
| ROE | -72.6% | -147.0% | -101.4% | -76.7% | -63.7% |
| ROA | -60.0% | -125.5% | -56.8% | -68.1% | -57.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ASCELIA PHARMA AB dividends
ASCELIA PHARMA AB has not paid dividends in the last 4 fiscal years.
Who owns ASCELIA PHARMA AB
- Insiders 13.35%
- Institutions 21.69%
- Public & others 64.96%
- Shares outstanding 134M
- Free float 122M
ASCELIA PHARMA AB company profile
- Company name
- ASCELIA PHARMA AB
- Ticker
- 7ZA.F
- ISIN
- SE0010573113
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- Hyllie Boulevard 34, Malmö, Sweden, 215 32
- Phone
- 46 7 35 17 91 18
- Website
- ascelia.com
About ASCELIA PHARMA AB
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
ASCELIA PHARMA AB management
4- Mr. Magnus O. CorfitzenChief Executive Officer · born 1975
- Jennie WilborgssonChief Operating Officer · born 1984
- Mr. Andreas L. Norlin Ph.D.Chief Scientific Officer · born 1970
- Mr. Mikael WidellHead of IR & Communications · born 1958